1. 一般资料 :2017 年 3 月至 2018 年 12 月,经南通市第四人民医院伦理委员会同意和患者签署知情同意书,随机抽样收集在精神科住院 40 岁以上符合 SCZ 组国际疾病分类(ICD) - 10 诊断标准[15]SCZ 患者 115 例的临床资料。依...
[2]Lan T, Chen M, Tang C, Deltenre P. Recent developments in the management of ascites in cirrhosis.United European Gastroenterol J. Published online February 10, 2024. [3]Bernardi M, Angeli P, Claria J, et al.Albumin ...
Causes of death were classified by the ICD-10 codes. Liver-related deaths included liver cancer, cirrhosis and CLDs.#Among a total of 2,826,531 deaths in 2018, there were 85,807 (3.04%) with underlying CLD (mean age at death 63.0 years, 63.8% male, 70.8% white). Liver-related ...
First, as NAFLD cirrhosis lacks a formal ICD code in the Swedish NPR we had to rely on a combination of codes. This may have introduced some degree of outcome misclassification. However, most diagnoses of liver diseases have high PPV in Swedish registries [30,31]. We also excluded ...
Causes of death were classified by the ICD-10 codes. Liver-related deaths included liver cancer, cirrhosis and CLDs. Results: Among a total of 2,826,531 deaths in 2018, there were 85,807 (3.04%) with underlying CLD (mean age at death 63.0 years, 63.8% male, ...
(36.85)Cirrhosis385 (6.18)10228 (2.30)Alcohol345 (5.54)11811 (2.76)OSA310 (4.98)12581 (2.94)EthnicityCaucasian4527 (72.67)304601 (71.18)Non- Caucasian1703 (27.33)123329 (28.82)Charlson Comorbidity Index3 OR >36230 (100)364040 (85.07)Mortality325 (5.22)32138 (7.51)Mean (95% CI)Mean (95% ...
Inclusion criteria often require liver biopsy showing fibrosis (F2/3) or cirrhosis (F4) and nonalcoholic steatohepatitis (NASH). However, histological criteria pose a serious obstacle for recruitment. Aims: Characterize the relevance of liver biopsies in the selection of patients with NAFLD. Methods:...
[2]Lan T, Chen M, Tang C, Deltenre P. Recent developments in the management of ascites in cirrhosis.United European Gastroenterol J. Published online February 10, 2024. [3]Bernardi M, Angeli P, Claria J, et al.Albumin in decompensated cirrhosis: new concepts and perspectives[J]. Gut. ...
NAFLD is the most common liver disease worldwide and can progress to inflammatory hepatitis, cirrhosis, and hepatocellular carcinoma. Due to an imbalance between hepatic fatty acid uptake and removal, the hallmarks of NAFLD are metabolic disorders and lipotoxic hepatocyte damage. It is imperative to ...
The REVERSE trial (NCT03439254) in NASH-cirrhosis patients is in progress. Response rate for OCA and other FXR agonists in NASH is about 25%, and this aspect points to the need for combination therapy with agents acting at different levels in NAFLD/NASH (See related paragraph). Tropifexor,...